SpringWorks Therapeutics, Inc. Stock price

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:30:09 2024-02-28 pm EST 5-day change 1st Jan Change
49.6 USD -4.73% Intraday chart for SpringWorks Therapeutics, Inc. +0.57% +35.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * 78.79M Sales 2025 * 244M Capitalization 3.84B
Net income 2024 * -379M Net income 2025 * -255M EV / Sales 2024 * 45.2 x
Net cash position 2024 * 273M Net cash position 2025 * 451M EV / Sales 2025 * 13.9 x
P/E ratio 2024 *
-9.4 x
P/E ratio 2025 *
-15.4 x
Employees 227
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.96%
More Fundamentals * Assessed data
Dynamic Chart
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer CI
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating MT
Transcript : SpringWorks Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 07:30 AM
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday MT
SpringWorks Therapeutics Prices $275 Million Share Offering MT
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours MT
Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating MT
More news
1 day+7.41%
1 week+6.66%
Current month+17.99%
1 month+22.84%
3 months+150.70%
6 months+87.03%
Current year+42.66%
More quotes
1 week
46.45
Extreme 46.45
52.88
1 month
41.20
Extreme 41.2
53.78
Current year
35.66
Extreme 35.66
53.78
1 year
18.00
Extreme 18
53.78
3 years
13.60
Extreme 13.6
89.75
5 years
13.60
Extreme 13.6
96.48
10 years
13.60
Extreme 13.6
96.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 17-07-31
Chairman 66 17-07-31
Director of Finance/CFO 64 19-07-31
Members of the board TitleAgeSince
Director/Board Member 67 19-07-31
Director/Board Member 68 17-07-31
Director/Board Member 61 22-07-13
More insiders
Date Price Change Volume
24-02-28 49.46 -5.01% 1 096 215
24-02-27 52.07 +7.41% 2,008,778
24-02-26 48.48 -1.30% 1,482,329
24-02-23 49.12 +0.02% 456,763
24-02-22 49.11 -0.22% 1,112,086

Delayed Quote Nasdaq, February 27, 2024 at 04:00 pm EST

More quotes
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. It has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. Its product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI), in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
52.07 USD
Average target price
64.91 USD
Spread / Average Target
+24.65%
Consensus
  1. Stock
  2. Equities
  3. Stock SpringWorks Therapeutics, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW